Related Documents - GARFIELD-AF Registry

Publications Related to

Filtered by:

All

Manuscripts

Abstracts

Other Publications

Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation

Fox KAA, Velentgas P, Camm AJ, Bassand J-P, Fitzmaurice DA, Gersh BJ, Goldhaber SZ, Goto S, Haas S, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Dabrowski E, Luo K, Gibbs L, Kakkar AK, for the GARFIELD-AF Investigators

External Link

Changes in anticoagulant prescription in Dutch patients with recent-onset atrial fibrillation: observations from the GARFIELD-AF registry

Seelig J, F. W. A. Verheugt FWA, Hemels MEW, Illingworth L, Lucassen A, Adriaansen H,
Bongaerts MCM, Pieterse M, Herrman JPR, Hoogslag P, Hermans W, Groenemeijer BE,
Boersma LVA, Pieper KS, ten Cate H, for the GARFIELD-AF Investigators

External Link

New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF

Goto S, Goto S, Pieper KS, Bassand J-P, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Haas S, Parkhomenko A, Oto A, Misselwitz F, Turpie AGG, Verheugt FWA, Fox KAA, Gersh BJ, Kakkar AK, for the GARFIELD-AF Investigators

External Link

Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry

Hacke W, Bassand J-P, Virdone S, Camm AJ, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Kayani,
Mantovani LG, Misselwitz F , Pieper KS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK, for the
GARFIELD-AF Investigators

External Link

Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF

Verheugt FWA, Ambrosio G, Atar D, Bassand J-P, Camm AJ, Costabel JP, Fitzmaurice DA, Illingworth L, Goldhaber SZ, Goto S, Haas S, Jansky P, Kayani G, Stepinska J, Turpie AGG, van Eickels M, Kakkar AK,for the GARFIELD-AF Investigators

External Link

The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events

Atar D, Berge E, Le Heuzey J-Y, Virdone S, Camm A.J, Steffel J, Gibbs H, Goldhaber SZ,
Goto S, Kayani G, Misselwitz F, Stepinska J, Turpie AGG, Bassand J-P, Kakkar AK, for the
GARFIELD-AF Investigators

External Link

Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF

Haas S, Camm AJ, Bassand J-P, Angchaisuksiri P, Cools F, Corbalan R, Gibbs H, Jacobson B, Koretsune Y, Mantovani LG, Misselwitz F, Panchenko E, Ragy HI, Stepinska J, Turpie AGG, Sawhney JPS, Steffel J, Lim TW, Pieper KS, Virdone S, Verheugt FWA, Kakkar AK, for the GARFIELD-AF Investigators

External Link

Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation A Report From the GARFIELD-AF Registry

Corbalan R, Bassand J-P, Illingworth L, Ambrosio G, Camm AJ, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Kakkar AK,for the GARFIELD-AF Investigators

External Link

Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: Insights from the GARFIELD-AF registry

Jerjes-Sanchez C, Corbalan R, Barretto ACP, Luciardi HL, Jagan A, Illingworth L, Pieper KS, Kayani G, for the GARFIELD-AF Investigators

External Link

Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-AF Registry

Goto S, Angchaisuksiri P, Bassand J-P, Camm A.J, Dominguez H, Illingworth L, Gibbs H, Goldhaber SZ, Goto S, Jing J-Z, Haas S, Kayani G, Koretsune Y, Lim TW, Oh S, Sawhney JPS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK, for the GARFIELD-F Investigators

External Link

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in Japan: Insights from the GARFIELD-AF Registry.

Koretsune Y, Etoh T, Katsuda Y, Suetsugu T, Kumeda K, Sakuma I, Eshima K, Shibuya M, Ando S, Yokota N, Goto S, Piper KS, Jagan A, Kakkar AK, for the GARFIELD-AF investigators.

External Link

Early risks of death, stroke/systemic embolism and major bleeding in patients with newly diagnosed atrial fibrillation: Results from the GARFIELD-AF registry.

Bassand J-P, Virdone S, Goldhaber SZ, Camm AJ, Fitzmaurice DA, Fox KAA, Goto S, Haas S, Hacke W, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK, for the GARFIELD-AF investigators.

External Link

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights into the GARFIELD-AF Registry.

Sawhney JPS, Kothiwale VA, Bisne V, Durgaprased R, Jadhav P, Chopda M, Vanajakshamma V, Meena R, Vijayaraghavan G, Chawala K, Jagan A, Pieper KS, Camm AJ, Kakkar AK, for the GARFIELD-AF investigators.

External Link

Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry

Cools F, Wollaert B, Vervoort G, Verstraete S, Voet J, Hermans K, Heyse A, De Wolf A, Hollanders G, Boussy T, Anne W, Vercammen J, Faes D, Beutels M, Mairesse G, Purnode P, Blankoff I, Vandergoten P, Capiau L, Allu J, Bassand J-P, Kayani G, for the GARFIELD-AF Investigators

External Link

Stroke prevention, 1-year clinical outcomes and healthcare resource utilization in patients with atrial fibrillation in France: Data from the GARFIELD-AF registry

Le Heuzey J-Y, Bassand J-P, Berneau J-B,Cozzolino P, Angiolella LD, Doucet B,Mantovani LG,
Martelet M, Mouallem J, Muller J-J, Pieper K, for the GARFIELD-AF Investigators

External Link

Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry.

Apenteng PN, Gao H, Hobbs FDR, Fitzmaurice DA, On behalf of UK GARFIELD-AF Investigators and GARFIELD-AF Steering Committee.
BMJ Open 2018; 8:e018905.

External Link

Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.

Bassand JP, Accetta G, Al Mahmeed W, Corbalan R, Eikelboom J, Fitzmaurice DA, Fox KAA, Gao H, Goldhaber SZ, Goto S, Haas S, Kayani G, Pieper K, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK, GARFIELD-AF Investigators.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784935/pdf/pone.0191592.pdf

External Link

Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: Insights from the GARFIELD-AF registry.

Verheugt FWA, Gao H, Mahmeed WA, Ambrosio G, Angchaisuksiri P, Atar D, Bassand J.P., Camm A.J., Cools F, Eikelboom J, Kayani G, Lim TW, Misselwitz F, Pieper KS, Eickels MV, Kakkar AK, for the GARFIELD-AF Investigators.
https://doi.org/10.1093/eurheartj/ehx730

External Link

Risk Factors and Prescribed Antithrombotic Therapy in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation in Russian Population: Data From the GARFIELD-AF Registry.

Panchenko EP, Accetta G, Libis PA, Miller OH, Novikova TN, Nagibovich OA on behalf of
the Russian participants in the register GARFIELD-AF. [Article in Russian]

External Link

International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.

Steinberg BA, Gao H, Shrader P, Pieper K, Thomas L, Camm AJ, Ezekowitz MD, Fonarow GC, Gersh BJ, Goldhaber S, Haas S, Hacke W, Kowey PR, Ansell J, Mahaffey KW, Naccarelli G, Reiffel JA, Turpie AGG, Verheugt FWA, Piccini JP, Kakkar AK, Peterson ED, Fox KAA, For the GARFIELD-AF ORBIT-AF Investigators.
http://www.ahjonline.com/article/S0002-8703(17)30241-7/pdf

External Link

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation

Fox KAA, Lucas JE, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Oto A, Mantovani LG, Misselwitz F, Piccini JP, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators.
BMJ Open. 2017 Dec 21;7(12):e017157.

External Link

Características basales, manejo de terapias antitrombóticas y pronóstico de pacientes chilenos con FA no valvular. Lecciones del Registro GARFIELD AF en Chile

Corbalán R, Conejeros C, Rey C, Stockins B, Eggers G, Astudillo C,Lanas F, Potthoff S, Houzvic C,MonteCinos H, Charme G,Bugueño C, Aguilar J, Arriagada G,Marín P, larico M,en Representación Del Grupo GARFIELD-AF.
Rev Med Chile 2017; 145: 963-971.

External Link

Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Fox KAA, Accetta G, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Kayani G, Kakkar AK; GARFIELD-AF Investigators.
Eur Heart J Qual Care Clin Outcomes 2017 Aug 16. doi: 10.1093/ehjqcco/qcx030

External Link

Evolving quality standards for large-scale registries: the GARFIELD-AF experience.

Fox KAA, Gersh BJ, Traore S, Camm AJ, Kayani G, Krogh A, Shweta S, Kakkar AK; GARFIELD-AF Investigators. Eur Heart J Qual Car Clin Outcomes. 2017;3(2):114-122.

External Link

Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspectives from the GARFIELD-AF registry.

Camm AJ, Accetta G, Al Mahmeed W, Ambrosio G, Goldhaber SZ, Haas S, Jansky P, Kayani G, Misselwitz F, Oh S, Oto A, Raatikainen P, Steffel J, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. BMJ Open 2017;7(3):e014579

External Link

Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.

Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand JP, Berge E, Cools F, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Kayani G, Koretsune Y, Mantovani LG, Oh S, Turpie AG, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. Heart 2017;103(4):307-314

External Link

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

Bassand JP, Accetta G, Camm AJ, Cools F, Fitzmaurice DA, Fox KA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Mantovani LG, Misselwitz F, Ten Cate H, Turpie AG, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. Eur Heart J 2016;37(38):2882-2889

External Link

Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists.

Fitzmaurice DA, Accetta G, Haas S, Kayani G, Lucas Luciardi H, Misselwitz F, Pieper K, Ten Cate H, Turpie AG, Kakkar AK; GARFIELD-AF Investigators. Br J Haematol 2016;174(4):610-23.

External Link

Stroke prevention in AF patients in Poland and other European countries: insights from the GARFIELD-AF registry.

Stępińska J, Kremis E, Konopka A, Wożakowska-Kapłon B, Ruszkowski P, Kukla P, Kayani G. Kardiol Pol 2016;74(4):362-71.

External Link

Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The Prospective Global Anticoagulant Registry in the FIELD-Atrial Fibrillation.

Lip GY, Rushton-Smith SK, Goldhaber SZ, Fitzmaurice DA, Mantovani LG, Goto S, Haas S, Bassand JP, Camm AJ, Ambrosio G, Janský P, Mahmeed WA, Oh S, van Eickels M, Raatikainen P, Steffel J, Oto A, Kayani G, Accetta G, Kakkar AK; GARFIELD-AF Investigators. Circ Cardiovasc Qual Outcomes 2015;8(2 suppl 1):S12-20.

External Link

Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry.

Oh S, Goto S, Accetta G, Angchaisuksiri P, Camm AJ, Cools F, Haas S, Kayani G, Koretsune Y, Lim TW, Misselwitz F, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Int J Cardiol 2016;223:543-7.

External Link

The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) : Exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands.

Ten Cate V, Ten Cate H, Verheugt FW. Neth Heart J. 2016;24(10):574-80.

External Link

Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.

Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand JP, Berge E, Cools F, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Kayani G, Koretsune Y, Mantovani LG, Misselwitz F, Oh S, Turpie AG, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. Heart. 2016 Sep 19. pii: heartjnl-2016-309832. doi: 10.1136/heartjnl-2016-309832. [Epub ahead of print]

External Link

GARFIELD-AF - First data on healthcare of patients with atrial fibrillation in Germany

Haas S; im Namen des GARFIELD-AF Steering Committee. Dtsch Med Wochenschr 2015;140(suppl 1):S13-4. [Article in German]

External Link

Chinese subgroup analysis of the global anticoagulant registry in the FIELD (GARFIELD) registry in the patients with non-valvular atrial fibrillation

Sun Y, Hu D; Chinese Investigators of GARFIELD. Zhonghua Xin Xue Guan Bing Za Zhi 2014;42(10):846-50. [Article in Chinese]

External Link

Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD Registry.

Kakkar AK, Mueller I, Bassand J-P, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GYH, Mantovani LG, Turpie AGG, van Eickels M, Misselwitz F, Rushton-Smith S, Kayani G, Wilkinson P, Verheugt FWA, for the GARFIELD Registry Investigators. PLOS ONE 2013;8(5):e63479.

External Link

An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol.

Apenteng PN, Murray ET, Holder R, Hobbs FDR, Fitzmaurice DA; UK GARFIELD Investigators and GARFIELD Steering Committee. BMC Cardiovascular Disorders 2013;13:31. UK protocol paper.

External Link

International longitudinal registry of patients with atrial fibrillation at risk of stroke: GARFIELD (Global Anticoagulant Registry in the FIELD).

Kakkar AK, Mueller I, Bassand J-P, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GYH, Mantovani LG, Verheugt FWA, Jamal W, Misselwitz F, Rushton-Smith S, Turpie AGG, for the GARFIELD Registry Investigators. Am Heart J 2012;163(1):13-19.e1. Methods paper.

External Link

Abstracts

Different short- and long-term prognostic implications of bleeding in patients with newly diagnosed atrial fibrillation: Real world evidence from the GARFIELD-AF registry

European Society of Cardiology (Paris, France, 31st August - 4th September 2019)-
Bassand J-P., Illingworth L., Badoz M., Camm A.J., Fitzmaurice D.A., Fox K.A.A., Goldhaber S.Z., Goto S., Haas S., Hacke W., Mantovani L.G., Pieper K.S., Turpie A.G.G., Verheugt F.W.A., Kakkar A.K., for the GARFIELD-AF Investigators

External Link

Predictors of intracranial haemorrhage in patients with atrial fibrillation: Insights from the GARFIELD-AF and ORBIT-AF registries

European Society of Cardiology (Paris, France, 31st August - 4th September 2019)-
Lim T.W., Camm A.J., Virdone S., Singer D.E., Bassand J-P, Fonarow G.C., Fox K.A.A., Ezekowitz M., Gersh B.J., Hylek E., Kakkar A.K, Mahaffey K.W., Pieper K.S., Peterson E.D., Piccini J.P.,for the GARFIELD-AF Investigators

External Link

Balancing risk and benefit in patients with atrial fibrillation: the GARFIELD-AF risk score

European Society of Cardiology (Paris, France, 31st August - 4th September 2019)-
Fox K.A.A., Virdone S., Pieper K.S.,for the GARFIELD-AF Investigators

External Link

Haematuria is not elevated in AF patients treated with NOACs versus VKAs: GARFIELD-AF study

European Society of Cardiology (Paris, France, 31st August - 4th September 2019) - Verstraete S., Virdone S., Bassand J-P., Cools F., Pieper K.S., Kayani G., Kakkar A.K., for the GARFIELD-AF Investigators

External Link

The risk of permanent discontinuation of oral anticoagulation in patients with atrial fibrillation: data from the GARFIELD-AF registry

American Heart Association (Chicago, IL, USA, 10-14 Nov 2018). Cools F., Camm A.J., Bassand J-P., Verheugt F.W.A., Yang S., Tsiatis A., Fitzmaurice D.A., Goldhaber S.Z., Goto S., Haas S., Misselwitz F., Turpie A.G.G., Fox K.A.A., Kakkar A.K., for the GARFIELD-AF Investigators

External Link

In newly diagnosed atrial fibrillation patients, a history of stroke is a better predictor of events than a history of TIA

World Stroke Congress (Montreal, Canada, 17-20, Oct 2018)- Hacke W., Bassand J-P.,Camm A.J., Fitzmaurice D.A., Goldhaber S.Z., Virdone S., Goto S., Haas S., Kayani G., Mantovani L.Z., Pieper K.S., Misselwitz F., Van Eickels M., Turpie A.G.G., Verheugt F.W.A., Kakkar A.K., for the GARFIELD-AF Investigators.

External Link

Evaluation of the effect of oral anticoagulants on all-cause mortality within 3 months of the diagnosis of atrial fibrillation: results from the GARFIELD-AF prospective registry

European Society of Cardiology (Munich, Germany, 25th August - 29th August 2018) - Fox, KAA, Berchuck S, Camm AJ, Bassand J-P, Fitzmaurice DA, Gersh BJ, Goldhaber SZ, Goto S, Haas S, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Kakkar AK on behalf of GARFIELD-AF Investigators.

External Link

Role of cardioversion in the management of non-valvular atrial fibrillation: insights from the GARFIELD-AF registry

European Society of Cardiology (Munich, Germany, 25th August - 29th August 2018) - Schirripa V, Radic P, Pieper KS, Illingworth L, Le Heuzey J-Y, Jansky P, Fitzmaurice DA, Connolly S, Cappato R, Camm AJ, Atar D , Kakkar AK on behalf of GARFIELD-AF Investigators.

External Link

The effect of non-recommended dosing of non-vitamin K antagonist oral anticoagulants (NOACs) on 1-year mortality in patients with newly diagnosed AF? Results from the GARFIELD-AF registry

European Society of Cardiology (Munich, Germany, 25th August - 29th August 2018) - Camm AJ, Cools F, Virdone S, Bassand J-P, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S,Haas S, Mantovani LG, Pieper KS, Turpie AGG, Verheugt FWA, Kakkar AK on behalf of GARFIELD-AF Investigators.

External Link

The economic burden attributable to atrial fibrillation in nine European countries: perspectives from the GARFIELD-AF registry

European Society of Cardiology (Munich, Germany, 25th August - 29th August 2018) - Cozzolino P, Ambrosio G, Bassand J-P, Ten Cate H, Cools F, Darius H, Fitzmaurice DA, Haas S, Le Heuzey J-Y, Agnelli G, Rosenkvist M, Stepinska J, Vinolas X, Mantovani LG, Kakkar AK on behalf of GARFIELD-AF Investigators.

External Link

Why do clinicians withhold anticoagulation in patients with atrial fibrillation and CHA2DS2VASc score of 2 or higher?

European Society of Cardiology (Munich, Germany, 25th August - 29th August 2018) - Siegal DM, Verbrugge F, Martin AC, Fiarresga A, Camm AJ, Pieper KS, Fox KAA, Bassand J-P, Haas S, Goldhaber SZ, Kakkar AK on behalf of GARFIELD-AF Investigators.

External Link

Why do clinicians prescribe oral anticoagulation in patients with atrial fibrillation despite a low CHA2DS2-VASc score?

European Society of Cardiology (Munich, Germany, 25th August - 29th August 2018) -Verbrugge FH, Martin A-C, Siegal DM, Fiarresga A, Pieper KS, Camm AJ, Fox KAA, Bassand J-P, Haas S, Goldhaber SZ, Kakkar AK on behalf of GARFIELD-AF Investigators.

External Link

GARFIELD-AF prospective registry – Comparative effectiveness of oral anticoagulants in everyday practice

European Society of Cardiology (Munich, Germany, 25th August - 29th August 2018) -Camm AJ, Fox KAA, Virdone S, Bassand J-P, Fitzmaurice DA, Gersh BJ, Goldhaber SZ, Goto G, Haas S, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Kakkar AK on behalf of GARFIELD-AF Investigators.

External Link

GARFIELD-AF prospective registry – Adverse one-year outcomes for patients newly treated with oral anticoagulants plus antiplatelet therapy

European Society of Cardiology (Munich, Germany, 25th August - 29th August 2018) -Fox KAA, Velentgas P, Camm AJ, Bassand J-P, Fitzmaurice DA, Gersh BJ, Goldhaber SZ, Goto G, Haas S, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Kakkar AK on behalf of GARFIELD-AF Investigators.

External Link

One-year clinical outcomes and management of patients with ischeamic vs non-ischaemic cardiomyopathy and newly diagnosed atrial fibrillation: results from GARFIELD-AF

European Society of Cardiology (Barcelona, Spain, 26th August - 30th August 2017) - Corbalan R, Bassand J-P, Al Mahmeed W, Ambrosio G, Gao H, Gibbs H, Goldhaber SZ, Jerjes-Sanchez C, Le Heuzey J-Y, Panchenko E, Parkhomenko A, Barretto P, Steffel J, Stepinska J, Kakkar AK on behalf of GARFIELD-AF Investigators.

External Link

The burden of atrial fibrillation in the more populated European countries: perspectives from the GARFIELD-AF registry

European Society of Cardiology (Barcelona, Spain, 26th August -30th August 2017) - Mantovani L, Cozzolino P, Angiolella LD, Agnelli G, Ambrosio G, Camm AJ, Darius H, Fitzmaurice DA, Fox KAA, Kayani G, Keltai M, Le Heuzey J-Y, Pieper KS, Kakkar AK on behalf of GARFIELD-AF Investigators.

External Link

Global healthcare resource in 39,670 patients with AF: perspectives from GARFIELD-AF

European Society of Cardiology (Barcelona, Spain, 26th August - 30th August 2017) - Mantovani L, Cozzolino P, Ambrosio G, Ersanli M, Kayani G, Panchenko E, Raatikainen P, Stepinska J, Kakkar AK on behalf of GARFIELD-AF Investigators.

External Link

Which definition of hypertension best defines thromboembolic risk in patients with atrial fibrillation? Data from the GARFIELD-AF registry

European Society of Cardiology (Barcelona, Spain, 26th August -30th August 2017) - Camm AJ, Bassand J-P, Kayani G, Gao H, Kakkar AK on behalf of GARFIELD-AF Investigators.

External Link

Similar clinical outcomes of asymptomatic and symptomatic patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF

European Society of Cardiology (Barcelona, Spain, 26th August - 30th August 2017) - Gibbs H, Freedman B, Rosenqvist M, Al Mahmeed W, Ambrosio G, Camm AJ, Connolly SJ, Gao H, Jacobson B, Jerjes-Sanchez C, Kayani G, Oto A, Panchenko E, Ragy H, Kakkar AK on behalf of GARFIELD-AF Investigators.

External Link

Treatment and outcomes of patients with nonvalvular atrial fibrillation according to guideline-defined anticoagulation thresholds: results from the GARFIELD-AF registry.

American College of Cardiology (Washington, DC, USA, 17th March - 19th March 2017) - Camm AJ, Accetta G, Agnelli G, Bassand J-P, Goldhaber S, Kayani G, Misselwitz F, Oh S, Raatikainen P, Turpie A, van Eickels M, Kakkar A on behalf of GARFIELD-AF Investigators. JACC 2017;69(11):315. P1110-098, 17 March 2017

External Link

Early mortality in patients with new onset atrial fibrillation: results from the GARFIELD-AF registry.

American College of Cardiology (Washington, DC, USA, 17th March - 19th March 2017) - Goldhaber SZ, Camm AJ, Accetta G, Bassand J-P, Fitzmaurice D, Goto S, Haas S, Hacke W, Kayani G, Misselwitz F, Mantovani L, Turpie A, van Eickels M, Verheugt F, Kakkar A on behalf of GARFIELD-AF Investigators. JACC 2017;69(11):326. P1134M-11, 17 March 2017

External Link

The prescribing of antiplatelet therapy only in patients with nonvalvular atrial fibrillation: results from the GARFIELD-AF registry.

American College of Cardiology (Washington, DC, USA, 17th March - 19th March 2017) - Verheugt FWAA, Al Mahmeed W, Ambrosio G, Angchaisuksiri P, Atar D, Bassand J-P, Camm AJ, Cools F, Eikenboom JW, Gao H, Kayani G, Lim TW, Misselwitz F, van Eickels M, Kakkar A on behalf of GARFIELD-AF Investigators. JACC 2017;69(11):326. P1223M-05, 18 March 2017

External Link

Vitamin K antagonist control for patients with newly diagnosed atrial fibrillation in Eastern and Southeastern Asia: An analysis of event rates from GARFIELD-AF.

European Society of Cardiology (Rome, Italy, 27th August - 31st August 2016) - Goto S, Accetta G, Angchaisuksiri P, Camm AJ, Fitzmaurice DA, Haas S, Kayani G, Koretsune Y, Lim TW, Oh S, Schellong SM, ten Cate H, Turpie AGG, Kakkar AK on behalf of GARFIELD-AF Investigators. Eur Heart J 2015;36(suppl 1):544. P4971, 30 August 2016

External Link

Do baseline characteristics account for geographical variations in event rates in patients with newly diagnosed atrial fibrillation? The GARFIELD-AF registry.

European Society of Cardiology (Rome, Italy, 27th August - 31st August 2016) - Fox KAA, Accetta G, Darius H, Goto S, Kayani G, Koretsune Y, Oh S, Parkhomenko A, Sawhney JPS, Stepinska J, Kakkar AK on behalf of GARFIELD-AF Investigators. Eur Heart J 2015;36(suppl 1):544. P4100, 29 August 2016

External Link

Identifying patients with atrial fibrillation and truly low thromboembolic risk who are poorly characterised by CHA2DS-VASc: Superior performance of a novel machine learning tool in GARFIELD-AF.

European Society of Cardiology (Rome, Italy, 27th August - 31st August 2016) - Fox KAA, Lucas JE, Pieper KS, Bassand J-P, Camm AJ, Fitzmaurice DA, Hacke W, Kayani G, Oto A, Kakkar AK on behalf of GARFIELD-AF Investigators. Eur Heart J 2016;37(suppl 1):985, 7075, 29 August 2016

External Link

Evolving antithrombotic treatment patterns in patients with newly diagnosed atrial fibrillation in GARFIELD-AF.

European Society of Cardiology (London, UK, 29 August−2 September 2015) - Camm AJ, Ambrosio G, Atar D, Berge E, Cools F, Goldhaber SZ, Kayani G, Koretsune Y, Turpie AGG, Kakkar AK on behalf of GARFIELD-AF Investigators. Eur Heart J 2015;36(suppl 1):745. P4404, 31 August 2015.

External Link

Patterns of uptake of non-vitamin K antagonist oral anticoagulants in Europe: an analysis from the GARFIELD-AF registry.

European Society of Cardiology (London, UK, 29 August−2 September 2015) - Camm AJ, Ambrosio G, Atar D, Bassand J-P, Cools F, Fox KAA, Jansky P, Keltai M, Le Heuzey J-Y, Kakkar AK on behalf of GARFIELD-AF Investigators. Eur Heart J 2015;36(suppl 1):242. P1513, 30 August 2015.

External Link

Stroke, major bleeding and mortality in newly diagnosed atrial fibrillation with moderate-to-severe chronic kidney disease: results from GARFIELD-AF.

European Society of Cardiology (London, UK, 29 August−2 September 2015) - Goto S, Atar D, Bassand J-P, Fox KAA, Goldhaber SZ, Misselwitz F, Oh S, Turpie AGG, Verheugt F, Kakkar AK on behalf of GARFIELD-AF Investigators. Eur Heart J 2015;36(suppl 1):987. P5598, 1 September 2015.

External Link

Risk profiles and 1-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

International Society on Thrombosis and Haemostasis (Toronto, Canada, 20−25 June 2015) - Kakkar AK, Accetta G, Agnelli G, Angchaisuksiri P, Bassand J-P, Chiswell K, Cools F, Fitzmaurice DA, Gibbs H, Goldhaber SZ, Goto S, Haas S, Jacobson B, Jerjes-Sanchez C, Kayani G, Mantovani LG, Misselwitz F, ten Cate H, Turpie AG, van Eickels M, Verheugt FW, Camm J and on behalf of GARFIELD-AF Investigators. J Thromb Haemost 2015;13(suppl 2):139. OR119, 22 June 2015.

External Link

Quality of vitamin k antagonist control and 1-year outcomes: a global perspective from the garfield-af registry.

International Society on Thrombosis and Haemostasis (Toronto, Canada, 20−25 June 2015) - Cate Ht, Haas S, Accetta G, Angchaisuksiri P, Camm J, Corbalan R, Eikelboom J, Fitzmaurice DA, Goldhaber SZ, Goto S, Jacobson B, Kayani G, Turpie AG, Kakkar AK and on behalf of GARFIELD-AF Investigators. J Thromb Haemost 2015;13(suppl 2):130. OR096, 22 June 2015.

External Link

Truly low-risk patients with newly diagnosed non-valvular atrial fibrillation at risk of stroke: 1-year outcomes from the GARFIELD Registry.

European Society of Cardiology (Barcelona, Spain, 30 August−3 September 2014)
- Bassand J-P, Goldhaber SZ, Camm J, Turpie AGG, Misselwitz F, Oh S, van Eickels M, Agnelli G, Raatikainen P, Kakkar AK, for the GARFIELD Investigators. Eur Heart J 2014;35(suppl 1):1108. P6246, 2 September 2014.

External Link

International normalized ratio control and 1-year outcomes in patients with newly diagnosed atrial fibrillation: the GARFIELD Registry.

European Society of Cardiology (Barcelona, Spain, 30 August−3 September 2014) - Haas S, Goto S, Fitzmaurice D, Eikelboom J, ten Cate H, Koretsune Y, Parkhomenko A, Angchaisuksiri P, Corbalan R, Jacobson B, for the GARFIELD Investigators. Eur Heart J 2014;35(suppl 1):1110. P6256, 2 September 2014.

External Link

Is cardiovascular death a primary driver of mortality in higher age groups of patients with non-valvular atrial fibrillation? Results from the GARFIELD Registry.

European Society of Cardiology (Barcelona, Spain, 30 August−3 September 2014) - Bassand J-P, Fitzmaurice D, Camm J, Cools F, Stepinska J, Corbalan R, Kayani G, Panchenko E, Kakkar AK, for the GARFIELD Investigators. Eur Heart J 2014;35(suppl 1):437. P2469, 31 August 2014.

External Link

Impact of gender on clinical outcomes in non-valvular atrial fibrillation: contemporary perspective from the GARFIELD Registry.

American Heart Association (Chicago, IL, USA, 15–19 November 2014) - Camm J, Goldhaber SZ, Ambrosio G, Jansky P, Al Mahmeed W, Oh S, Van Eickels M, Raatikainen P, Steffel J, Chu E, Accetta G, Kayani G, Kakkar AK, for the GARFIELD Investigators. Circulation 2014;130:A20326. 16 November 2014.

External Link

Event rate in patients with atrial fibrillation who discontinue oral anticoagulant therapy early: results from the GARFIELD Registry.

American Heart Association (Chicago, IL, USA, 15–19 November 2014) - Goto S, Cools F, Verheugt FWA, Lim TW, Turpie AGG, Van Eickels M, Kayani G, Agnelli G, Angchaisuksiri P, Jacobson B, Kakkar AK, for the GARFIELD Investigators. Circulation 2014;130:A19998. 17 November 2014.

External Link

Use of antithrombotic therapies and outcomes in patients with atrial fibrillation and heart failure: insights from the GARFIELD Registry.

American Heart Association (Chicago, IL, USA, 15–19 November 2014) - Corbalan R, Pereira Barretto AC, Ambrosio G, Al Mahmeed W, Le Heuzey J-Y, Kayani G, Jerjes-Sanchez C, Stepinska J, Parkhomenko A, Steffel J, Panchenko E, Kakkar AK, for the GARFIELD Investigators. irculation 2014;130:A18738. 19 November 2014.

External Link

Atrial fibrillation treatment paradox: characteristics of and first-year events in patients not treated with vitamin K antagonists compared to treated patients. The GARFIELD Registry.

American College of Cardiology (San Francisco, CA, USA, 9–11 March 2013) - Bassand J-PL, Rushton-Smith S, Camm AJ, Goldhaber SZ, Goto S, Haas S, Mueller I, Turpie AGG, Kakkar A, for the GARFIELD Investigators. JACC 2013;61(10):E379. P49, 10 March 2013.

External Link

Outcomes after rhythm versus rate control in patients with atrial fibrillation: the international prospective GARFIELD Registry.

European Society of Cardiology (Amsterdam, Netherlands, 31 August−4 September 2013) - Berge E, Atar D, Le Heuzey J-Y, Connolly S, Fitzmaurice DA, Camm AJ, Jansky P, Rushton-Smith SK, Kayani G, Kakkar AK. Eur Heart J 2013;34(suppl 1):103. P551, 31 August 2013.

External Link

One-year outcomes in new versus permanent atrial fibrillation: insights from the prospective, international GARFIELD Registry.

European Society of Cardiology (Amsterdam, Netherlands, 31 August−4 September 2013)
- Camm AJ, Turpie AGG, Goto S, Stepinska J, Le Heuzey J-Y, Misselwitz F, Corbalan R, Rushton-Smith SK, Kayani G, Kakkar AK. Eur Heart J 2013;34(suppl 1):954. P5137, 3 September 2013.

External Link

Outcomes at 1 year in atrial fibrillation patients with versus without an acute coronary syndrome: insights from the prospective GARFIELD Registry.

European Society of Cardiology (Amsterdam, Netherlands, 31 August−4 September 2013)
- Verheugt FWA, Goldhaber SZ, Atar D, Camm AJ, Ambrosio G, Jansky P, Stepinska J, Rushton-Smith SK, Kayani G, Kakkar AK. Eur Heart J 2013;34(suppl 1):669. 3735, 2 September 2013.

External Link

Regional differences in use of antithrombotic therapy for stroke prevention in atrial fibrillation and associated outcomes: European and Asian insights.

European Society of Cardiology (Amsterdam, Netherlands, 31 August−4 September 2013)
- Goto S, Oh S, Cools F, Koretsune Y, Angchaisuksiri P, Rushton-Smith SK, Kayani G, Wilkinson P, Kakkar AK. Eur Heart J 2013;34(suppl 1):790. P4277, 2 September 2013.

External Link

One-year outcomes in atrial fibrillation patients with versus without a previous stroke or transient ischaemic attack: findings from the international prospective GARFIELD Registry.

European Society of Cardiology (Amsterdam, Netherlands, 31 August−4 September 2013)
- Kakkar AK, Bassand J-P, Goldhaber SZ, Agnelli G, Atar D, Berge E, Cools F, Haas S, Rushton-Smith SK, Hacke W. Eur Heart J 2013;34(suppl 1):61. P386, 31 August 2013.

External Link

Direct current conversion and clinical events at 1 year in patients with non-valvular atrial fibrillation. The Global Anticoagulant Registry in the FIELD (GARFIELD).

European Society of Cardiology (Amsterdam, Netherlands, 31 August−4 September 2013)
- Le Heuzey J-Y, Goto S, Verheugt FWA, Cools F, Rushton-Smith SK, Kayani G, Wilkinson P, Kakkar AK. Eur Heart J 2013;34(suppl 1):1045. P5633, 3 September 2013.

External Link

AK. One-year outcomes in atrial fibrillation patients with versus without coronary artery disease. The prospective Global Anticoagulant Registry in the FIELD (GARFIELD).

European Society of Cardiology (Amsterdam, Netherlands, 31 August−4 September 2013)
- Sanchez Diaz CJ, Goto S, Misselwitz F, Ambrosio G, Rushton-Smith SK, Kayani G, Wilkinson P, Kakkar Eur Heart J 2013;34(suppl 1):571. P3129, 2 September 2013.

External Link

Twelve-month outcomes in paroxysmal versus permanent atrial fibrillation: data from the prospective, international GARFIELD Registry.

European Society of Cardiology (Amsterdam, Netherlands, 31 August−4 September 2013)
- Turpie AGG, Camm AJ, Goto S, Stepinska J, Le Heuzey J-Y, Misselwitz F, Corbalan R, Rushton-Smith SK, Kayani G, Kakkar AK. Eur Heart J 2013;34(suppl 1):738. P4065, 2 September 2013.

External Link

Moderate-to-severe chronic kidney disease associated with 1-year all-cause mortality in patients newly diagnosed with non-valvular atrial fibrillation. The prospective international GARFIELD Registry.

American Heart Association (Dallas, TX, USA, 16–20 November 2013) - Goto S, Oh S, Bassand J-P, Gibbs H, Angchaisuksiri P, Rushton-Smith SK, Kayani G, Kakkar AK, Wilkinson P. Circulation 2013;128:A14514. 18 November 2013.

External Link

One year Australian outcome of cohort 1 of the Global Anticoagulant Registry in the Field (GARFIELD) Study.

Gibbs H. CSANZ, 2013. Heart Lung Circ 2013;22:S221. A525, 10 August 2013.

External Link

Inappropriate utilization of anticoagulation in patients with atrial fibrillation: the Global Anticoagulant Registry in the FIELD (GARFIELD) Registry.

American College of Cardiology (Chicago, IL, USA, 24–27 March 2012) - Lip G, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Verheugt FWA, Turpie AGG, Mueller I, Rushton-Smith S, Kakkar AK, for the GARFIELD Investigators. J Am Coll Cardiol 2012;59(13s1):E670-E670. P1236-167, 26 March 2012.

External Link

Gap between evidence-based guidelines and provision of oral anticoagulant therapy among patients newly diagnosed with atrial fibrillation: findings from Global Anticoagulant Registry in the FIELD.

European Stroke Conference (Lisbon, Portugal, 22–25 May 2012) - Hacke W, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Lip GYL, Mantovani L, Turpie AGG, Verheugt FWA, Misselwitz F, van Eickels M, Mueller I, Rushton-Smith S, Kakkar AK, for the GARFIELD Investigators. Cerebrovasc Dis 2012;33(suppl 2):816-817. P820, 24 May 2012.

External Link

Antithrombotic treatment patterns for stroke prevention in relation to age: insights from the Global Anticoagulant Registry in the FIELD (GARFIELD) evaluation.

European Society of Cardiology (Munich, Germany, 25–29 August 2012) - Bassand JP, Mueller I, Mantovani LG, Haas S, Goldhaber SZ, Goto S, Lip GYH, Rushton-Smith SK, Kakkar AK, for the GARFIELD Investigators. Eur Heart J 2012;33(suppl 1):52. P557, 26 August 2012.

External Link

Antithrombotic therapy for stroke prevention in patients with newly diagnosed atrial fibrillation and a history of acute coronary syndrome: the Global Anticoagulant Registry in the FIELD (GARFIELD).

European Society of Cardiology (Munich, Germany, 25–29 August 2012) - Verheugt FWA, Bassand JP, Turpie AGG, Fitzmaurice DA, Haas S, Goto S, Lip GYH, Mueller I, Rushton-Smith SK, Kakkar AK, for the GARFIELD Investigators. Eur Heart J 2012;33(suppl 1):1081. P5748, 29 August 2012.

External Link

Patterns of antithrombotic therapy and type of atrial fibrillation: insights from the Global Anticoagulant Registry in the FIELD (GARFIELD).

European Society of Cardiology (Munich, Germany, 25–29 August 2012) - Lip GYH, Rushton-Smith SK, Goto S, Verheugt FWA, Goldhaber SZ, Haas S, Bassand JP, Mueller I, Kakkar AK, for the GARFIELD Investigators. Eur Heart J 2012;33(suppl 1):54. P562, 26 August 2012.

External Link

Gender differences in use of antithrombotic therapy in atrial fibrillation: real-world perspective from the Global Anticoagulant Registry in the FIELD (GARFIELD).

European Society of Cardiology (Munich, Germany, 25–29 August 2012) - Lip GYH, Rushton-Smith SK, Goldhaber SZ, Fitzmaurice DA, Mantovani LG, Goto S, Haas S, Bassand JP, Mueller I, Kakkar AK, for the GARFIELD Investigators. Eur Heart J 2012;33(suppl 1):58. P578, 26 August 2012.

External Link

Regional differences in the use of antithrombotic therapy for stroke prevention in atrial fibrillation: European and Asian insights from the Global Anticoagulant Registry in the FIELD (GARFIELD).

European Society of Cardiology (Munich, Germany, 25–29 August 2012) - Goto S, Mueller I, Fitzmaurice DA, Haas S, Lip GYH, Turpie AGG, Goldhaber SZ, Rushton-Smith S, Kakkar AK, for the GARFIELD Investigators. Eur Heart J 2012;33(suppl 1):685. 4043, 28 August 2012.

External Link

Impact of renal function on use of antithrombotic therapy in atrial fibrillation: real-world perspective from the global anticoagulant registry in the FIELD.

European Society of Cardiology (Munich, Germany, 25–29 August 2012) - Goto S, Lip GYH, Goldhaber SZ, Verheugt FWA, Bassand JP, Turpie AGG, Mueller I, Rushton-Smith SK, Kakkar AK, for the GARFIELD Investigators. Eur Heart J 2012;33(suppl 1):967. 5290, 29 August 2012.

External Link

Outcomes and quality of anticoagulant control in patients newly diagnosed with non-valvular atrial fibrillation: insights from the worldwide GARFIELD Registry.

American Heart Association (Los Angeles, CA, USA, 4–6 November 2012) - Mantovani M, Mueller I, Bassand JP, Fitzmaurice D, Goldhaber SZ, Goto S, Haas S, Turpie AGG, Verheugt FWA, Rushton-Smith S, Kakkar AK; for the GARFIELD Investigators. Circulation 2012;126:A18357. P2171, 6 November 2012.

External Link

Atrial fibrillation in Australia – results from the Garfield study.

Gibbs H, Kakkar A. CSANZ, 2012. Heart Lung Circ 2012;21:S243. A586.

External Link

Prospective multicentre international registry of patients newly diagnosed with atrial fibrillation at risk of stroke: the Garfield Registry.

European Society of Cardiology (Paris, France, 27–31 August 2011) - Kakkar AK, on behalf of the Garfield Registry Investigators. Eur Heart J 2011;32(suppl 1):566. P3359 (W), 29 August 2011.

External Link

Other Publications

Pacientes con fibrilación auricular en riesgode accidente cerebrovascular. GARFIELD (Global Anticoagulant Registry in the FIELD). Patients with atrial fibrillation at risk of stroke.

Kakkar A, en representación del Comité Directivo y de Publicaciones del Registro GARFIELD/on behalf of the Global GARFIELD Steering Committee and Publication Committee. Rev Fed Arg Cardiol 2012;41(1):5-7. Editorial.

External Link

GARFIELD: a window on the real-life treatment of atrial fibrillation - South Africa joins the GARFIELD registry.

Aalbers J. Cardiovasc J Afr. 2012 Oct;23(9):528. News update.

External Link

Publications Related to document.write(new_string)

Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation

Changes in anticoagulant prescription in Dutch patients with recent-onset atrial fibrillation: observations from the GARFIELD-AF registry

New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF

Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry

Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF

The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events

Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF

Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation A Report From the GARFIELD-AF Registry

Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: Insights from the GARFIELD-AF registry

Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-AF Registry

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in Japan: Insights from the GARFIELD-AF Registry.

Early risks of death, stroke/systemic embolism and major bleeding in patients with newly diagnosed atrial fibrillation: Results from the GARFIELD-AF registry.

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights into the GARFIELD-AF Registry.

Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry

Stroke prevention, 1-year clinical outcomes and healthcare resource utilization in patients with atrial fibrillation in France: Data from the GARFIELD-AF registry

Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry.

Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.

Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: Insights from the GARFIELD-AF registry.

Risk Factors and Prescribed Antithrombotic Therapy in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation in Russian Population: Data From the GARFIELD-AF Registry.

International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation

Características basales, manejo de terapias antitrombóticas y pronóstico de pacientes chilenos con FA no valvular. Lecciones del Registro GARFIELD AF en Chile

Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Evolving quality standards for large-scale registries: the GARFIELD-AF experience.

Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspectives from the GARFIELD-AF registry.

Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists.

Stroke prevention in AF patients in Poland and other European countries: insights from the GARFIELD-AF registry.

Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The Prospective Global Anticoagulant Registry in the FIELD-Atrial Fibrillation.

Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry.

The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) : Exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands.

Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.

GARFIELD-AF - First data on healthcare of patients with atrial fibrillation in Germany

Chinese subgroup analysis of the global anticoagulant registry in the FIELD (GARFIELD) registry in the patients with non-valvular atrial fibrillation

Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD Registry.

An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol.

International longitudinal registry of patients with atrial fibrillation at risk of stroke: GARFIELD (Global Anticoagulant Registry in the FIELD).

Different short- and long-term prognostic implications of bleeding in patients with newly diagnosed atrial fibrillation: Real world evidence from the GARFIELD-AF registry

Predictors of intracranial haemorrhage in patients with atrial fibrillation: Insights from the GARFIELD-AF and ORBIT-AF registries

Balancing risk and benefit in patients with atrial fibrillation: the GARFIELD-AF risk score

Haematuria is not elevated in AF patients treated with NOACs versus VKAs: GARFIELD-AF study

The risk of permanent discontinuation of oral anticoagulation in patients with atrial fibrillation: data from the GARFIELD-AF registry

In newly diagnosed atrial fibrillation patients, a history of stroke is a better predictor of events than a history of TIA

Evaluation of the effect of oral anticoagulants on all-cause mortality within 3 months of the diagnosis of atrial fibrillation: results from the GARFIELD-AF prospective registry

Role of cardioversion in the management of non-valvular atrial fibrillation: insights from the GARFIELD-AF registry

The effect of non-recommended dosing of non-vitamin K antagonist oral anticoagulants (NOACs) on 1-year mortality in patients with newly diagnosed AF? Results from the GARFIELD-AF registry

The economic burden attributable to atrial fibrillation in nine European countries: perspectives from the GARFIELD-AF registry

Why do clinicians withhold anticoagulation in patients with atrial fibrillation and CHA2DS2VASc score of 2 or higher?

Why do clinicians prescribe oral anticoagulation in patients with atrial fibrillation despite a low CHA2DS2-VASc score?

GARFIELD-AF prospective registry – Comparative effectiveness of oral anticoagulants in everyday practice

GARFIELD-AF prospective registry – Adverse one-year outcomes for patients newly treated with oral anticoagulants plus antiplatelet therapy

One-year clinical outcomes and management of patients with ischeamic vs non-ischaemic cardiomyopathy and newly diagnosed atrial fibrillation: results from GARFIELD-AF

The burden of atrial fibrillation in the more populated European countries: perspectives from the GARFIELD-AF registry

Global healthcare resource in 39,670 patients with AF: perspectives from GARFIELD-AF

Which definition of hypertension best defines thromboembolic risk in patients with atrial fibrillation? Data from the GARFIELD-AF registry

Similar clinical outcomes of asymptomatic and symptomatic patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF

Treatment and outcomes of patients with nonvalvular atrial fibrillation according to guideline-defined anticoagulation thresholds: results from the GARFIELD-AF registry.

Early mortality in patients with new onset atrial fibrillation: results from the GARFIELD-AF registry.

The prescribing of antiplatelet therapy only in patients with nonvalvular atrial fibrillation: results from the GARFIELD-AF registry.

Vitamin K antagonist control for patients with newly diagnosed atrial fibrillation in Eastern and Southeastern Asia: An analysis of event rates from GARFIELD-AF.

Do baseline characteristics account for geographical variations in event rates in patients with newly diagnosed atrial fibrillation? The GARFIELD-AF registry.

Identifying patients with atrial fibrillation and truly low thromboembolic risk who are poorly characterised by CHA2DS-VASc: Superior performance of a novel machine learning tool in GARFIELD-AF.

Evolving antithrombotic treatment patterns in patients with newly diagnosed atrial fibrillation in GARFIELD-AF.

Patterns of uptake of non-vitamin K antagonist oral anticoagulants in Europe: an analysis from the GARFIELD-AF registry.

Stroke, major bleeding and mortality in newly diagnosed atrial fibrillation with moderate-to-severe chronic kidney disease: results from GARFIELD-AF.

Risk profiles and 1-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

Quality of vitamin k antagonist control and 1-year outcomes: a global perspective from the garfield-af registry.

Truly low-risk patients with newly diagnosed non-valvular atrial fibrillation at risk of stroke: 1-year outcomes from the GARFIELD Registry.

International normalized ratio control and 1-year outcomes in patients with newly diagnosed atrial fibrillation: the GARFIELD Registry.

Is cardiovascular death a primary driver of mortality in higher age groups of patients with non-valvular atrial fibrillation? Results from the GARFIELD Registry.

Impact of gender on clinical outcomes in non-valvular atrial fibrillation: contemporary perspective from the GARFIELD Registry.

Event rate in patients with atrial fibrillation who discontinue oral anticoagulant therapy early: results from the GARFIELD Registry.

Use of antithrombotic therapies and outcomes in patients with atrial fibrillation and heart failure: insights from the GARFIELD Registry.

Atrial fibrillation treatment paradox: characteristics of and first-year events in patients not treated with vitamin K antagonists compared to treated patients. The GARFIELD Registry.

Outcomes after rhythm versus rate control in patients with atrial fibrillation: the international prospective GARFIELD Registry.

One-year outcomes in new versus permanent atrial fibrillation: insights from the prospective, international GARFIELD Registry.

Outcomes at 1 year in atrial fibrillation patients with versus without an acute coronary syndrome: insights from the prospective GARFIELD Registry.

Regional differences in use of antithrombotic therapy for stroke prevention in atrial fibrillation and associated outcomes: European and Asian insights.

Publications Related to